Journals / Anadolu Kardiyoloji Dergisi / 2006 / Cilt: 6 - Sayı: 1

The effect of paclitaxel-eluting stents on restenosis

Paklitaksel salan stentlerin restenoz üzerine etkisi

Pages
18–23
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study suggests that drug-eluting stents may also have a preventive effect for the in-stent restenosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In our study we aimed to investigate the effects of paclitaxel-eluting stent on restenosis.
📊
Key Findings & Data:Methods: Sixteen porcine were randomly assigned to two groups (n=8 per group): control group animals received conventional stent implantation and study group animals -paclitaxel-eluting stent implantation.
💡
Conclusion & Impact:Conclusion: This study suggests that drug-eluting stents may also have a preventive effect for the in-stent restenosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In our study we aimed to investigate the effects of paclitaxel-eluting stent on restenosis. Methods: Sixteen porcine were randomly assigned to two groups (n=8 per group): control group animals received conventional stent implantation and study group animals -paclitaxel-eluting stent implantation. Both groups were treated with 300 mg acetylsalicylic acid and 75 mg clopidogrel daily. The degree of neointimal proliferation and effect of drug-eluting stent on restenosis were evaluated 6 weeks after by angiography and intravascular ultrasound (IVUS). Results: Angiographic in-stent restenosis was lower in paclitaxel-eluting stent group (12.50 ± 7.07% versus 41.25 ± 28.50%, p=0.001). The IVUS data demonstrated that paclitaxel group animals had larger minimal lumen area (8.76 ± 1.09 mm2 versus 6.23 ± 3.10 mm2, p=0.028), smaller mean neointimal proliferation area (1.03 ± 0.75 mm2 versus 3.55 ± 2.86 mm2, p=0.01) and mean percent stenosis (10.71 ± 8.10% versus 36.85 ± 30.93%, p=0.01). Conclusion: This study suggests that drug-eluting stents may also have a preventive effect for the in-stent restenosis.

Özet

Amaç: Stent içi restenoz girişimsel kardiyoloji uygulamalarının başarısını etkileyen en önemli problemdir. Çalışmamızda paklitaksel salan stentlerin stent-içi restenoz üzerine etkisi domuz modelinde değerlendirilmiştir. Yöntemler: On altı domuz deneğin 8'ine standart stent, 8'ine ise ilaç salan stent yerleştirildi. Deneklerin tümüne günlük 300 mg asetilsalisilik asit ve 75 mg klopidogrel verilmiş, 6 hafta sonra ise her iki grubun kontrol anjiyografi ve intravasküler ultrasonları (IVUS) yapılmıştır. Bulgular: Kontrol anjiyografisinde çalışma grubunda saptanan anjiyografik stent içi darlık %12.50 ± 7.07 iken, kontrol grubunda bu oran %41.25 ± 28.50 (p=0.001) bulunmuştur. Ortalama minimal lümen alanı (MLA) çalışma grubunda 8.76 ± 1.09 mm2, kontrol grubunda 6.23 ± 3.10 mm2 (p=0.028) iken ortalama neointimal proliferasyon alanı (NPA) çalışma grubunda 1.03 ± 0.75 mm2, kontrol grubunda 3.55 ± 2.86 mm2 (p=0.01) olarak ölçülmüştür. Ortalama darlık ise çalışma grubunda %10.71 ± 8.10, kontrol grubunda %36.85 ± 30.93 (p=0.01) olarak tespit edilmiştir . Sonuç: Çalışmamızda paklitaksel salan stentlerin stent içi restenozu önlediği domuz modelinde gösterilmiştir.

🔖

Cite This Article

DEMİRTAŞ, E., İDE, T., KURŞAKLIOĞLU, H., IŞIK, E., TÖRE, H. F., İYİSOY, A., KÖZ, C., YILDIRIM, V. (2022). The effect of paclitaxel-eluting stents on restenosis. Anadolu Kardiyoloji Dergisi, Cilt: 6 - Sayı: 1, 18–23. https://ajindex.com/articles/437259

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lowe HC, Oesterle SN, Khanchian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39: 183-93
  2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. for the RAVEL study group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80
  3. Chandrasekar B, Tanguay JF. Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model. J Am Coll Cardiol 2000; 36: 1972-8
  4. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995; 95: 1869-76
  5. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77:1561-5
  6. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14
  7. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-95
  8. Johnson GJ, Griggs TR, Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: analysis and recommendations. On Behalf of the Subcommittee on Animal, Cellular and Molecular Models of Thrombosis and Haemostasis of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 835-43
  9. Ryan TJ, Bauman WB, Kennedy JW. Guidelines for percutaneous transluminal coronary angioplasty. A report of American Heart Association/ American College of Cardiology Task Force on Diagnostic and Therapeutic Cardiovascular Procedures (Commitee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993; 88: 2987-3007
  10. Herdeg C, Oberhoff M, Karsch KR. Antiproliferative stent coatings: Taxol and related compounds. Semin Interv Cardiol 1998; 3: 197-9
  11. Hong MK, Mintz GS, Lee CW, et al. ASian Paclitaxel-Eluting Stent Clinical Trial. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003; 107: 517-20
  12. New G, Moses JW, Roubin GS, Leon MB, Colombo A, Iyer SS, et al. Estrogen-eluting, phospho